Clinical trials: Corneal Endothelial Decompensation
Corneal Edema, Corneal Endothelial Dysfunction
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
Corneal edema is the most common indication for corneal transplantation, accounting for approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK) procedures annually.
- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy
- Trial name
- NCT04894110
- Testing
- EO2002, EO2002 low dose, EO2002 mid dose
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emmecell
Corneal Edema, Fuchs
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells [mHCECs]), compared with a placebo injection, in…
- Conditions
- Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
- Trial name
- EMERALD (NCT07729137)
- Testing
- 150K cells, 500K cells
- Where
- 10 sites in United States
- Volunteers
- 121 people
- Sponsor
- Emmecell